Erythropoiesis is a highly regulated, multistep process in which hematopoietic stem cells commit to erythroid progenitors and then differentiate into mature enucleated red blood cells (RBCs). Erythroid disorders, in which abnormal erythrocyte maturation and/or morphology is associated with ineffective erythropoiesis, can result from direct impairment of medullary erythropoiesis (e.g., thalassemia syndromes), inherited bone marrow failure (e.g., Myelodysplastic Syndrome), red cell overproduction (e.g., Polycythemia Vera), or existing blood cell destruction (e.g., Sickle Cell Anemia). It can also be caused by immune-mediated RBC destruction or certain genetic diseases that predispose to abnormal RBC production or turnover. New therapeutic modalities for treating red cell disorders have emerged as a result of a better understanding of the disease pathophysiology and underlying molecular mechanisms, such as induction of fetal hemoglobin and interference with aberrant signaling pathways.
The goal of this Research Topic is to accelerate the publication of studies that contribute to our understanding of the cellular and molecular basis of erythropoiesis, as well as its clinical application to erythroid disorders. In addition, this Research Topic will cover all aspects of erythroid differentiation, from basic laboratory research to translational and clinical investigations, including erythrocyte hemostatic mechanisms, disorders, and hematologic oncology.
Original Research articles, Reviews and Mini-reviews are all welcome. All researchers working on this topic are cordially invited to submit their manuscripts.
This Research Topic may cover, but is not limited to, the following subtopics:
• Fine-tuning of erythroid differentiation to identify the potential drug targets for erythroid disorders;
• Pathology and disease biology of Myelodysplastic Syndrome and Myeloproliferative Neoplasms with dyserythropoiesis;
• Molecular diagnostics and therapeutics of erythroid disorders, including Anaemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms;
• Pathophysiology of Anaemia in cancer.
Erythropoiesis is a highly regulated, multistep process in which hematopoietic stem cells commit to erythroid progenitors and then differentiate into mature enucleated red blood cells (RBCs). Erythroid disorders, in which abnormal erythrocyte maturation and/or morphology is associated with ineffective erythropoiesis, can result from direct impairment of medullary erythropoiesis (e.g., thalassemia syndromes), inherited bone marrow failure (e.g., Myelodysplastic Syndrome), red cell overproduction (e.g., Polycythemia Vera), or existing blood cell destruction (e.g., Sickle Cell Anemia). It can also be caused by immune-mediated RBC destruction or certain genetic diseases that predispose to abnormal RBC production or turnover. New therapeutic modalities for treating red cell disorders have emerged as a result of a better understanding of the disease pathophysiology and underlying molecular mechanisms, such as induction of fetal hemoglobin and interference with aberrant signaling pathways.
The goal of this Research Topic is to accelerate the publication of studies that contribute to our understanding of the cellular and molecular basis of erythropoiesis, as well as its clinical application to erythroid disorders. In addition, this Research Topic will cover all aspects of erythroid differentiation, from basic laboratory research to translational and clinical investigations, including erythrocyte hemostatic mechanisms, disorders, and hematologic oncology.
Original Research articles, Reviews and Mini-reviews are all welcome. All researchers working on this topic are cordially invited to submit their manuscripts.
This Research Topic may cover, but is not limited to, the following subtopics:
• Fine-tuning of erythroid differentiation to identify the potential drug targets for erythroid disorders;
• Pathology and disease biology of Myelodysplastic Syndrome and Myeloproliferative Neoplasms with dyserythropoiesis;
• Molecular diagnostics and therapeutics of erythroid disorders, including Anaemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms;
• Pathophysiology of Anaemia in cancer.
